Medullary cancer
Drug research and approvals for medullary cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 107 studies of medullary cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 107
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisNCT07914764 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Aug 1, 2026
- FES PET/MRI for Occult Disease in Lobular Breast CancerNCT07910474 · Phase 4 · University of Wisconsin, Madison · starts Nov 1, 2026
- Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryNCT07762885 · Phase 3 · Fudan University · starts Jul 1, 2026
- Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryNCT07762924 · Phase 2 · Fudan University · starts Sep 1, 2026
- Personalized Prone Immobilization for Accelerated Partial Breast RadiotherapyNCT07711847 · Not applicable · HeroSupport SA · starts Jul 2, 2026
- Predictive Biomarkers for Early Diagnosis of Pancreatic Ductal Adenocarcinoma (PDAC)NCT07709052 · Not reported · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis · starts Oct 21, 2026
- [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07702292 · Phase 2 · Blue Earth Diagnostics · starts Jun 30, 2026
- Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic CancerNCT07659639 · Not applicable · Fondazione Policlinico Universitario Campus Bio-Medico · starts Sep 1, 2025
- Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid TumorsNCT07628634 · Early Phase 1 · University of California, Irvine · starts May 1, 2026
Approved 3
- VandetanibTyrosine-protein kinase SRC inhibitor
- SelpercatinibTyrosine-protein kinase receptor RET inhibitor
- PralsetinibTyrosine-protein kinase receptor RET inhibitor
Phase 3 1
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
Phase 2 12
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- PazopanibMacrophage colony stimulating factor receptor inhibitor
- PonatinibBcr/Abl fusion protein inhibitor
- SunitinibMacrophage colony stimulating factor receptor inhibitor
- PasireotideSomatostatin receptor 5 agonist
- VorinostatHistone deacetylase 1 inhibitor
- PembrolizumabProgrammed cell death protein 1 inhibitor
- NintedanibPlatelet-derived growth factor receptor inhibitor
- CatequentinibVascular endothelial growth factor receptor 2 inhibitor
- TanespimycinHeat shock protein HSP90 inhibitor
Phase 1 or earlier 6
- Fludarabine
- RanitidineHistamine H2 receptor antagonist
- OmeprazolePotassium-transporting ATPase inhibitor
- Bortezomib26S proteasome inhibitor
- CyclophosphamideDNA inhibitor
- Gelatin
How its trials ended
49 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 8 whose ending is known, 38% met their primary endpoint, 13% missed it and 50% stopped early.
- Ongoing2143%
- Completed, result not reported1837%
- Met its primary endpoint36%
- Stopped: other or unclear36%
- Status unknown24%
- Missed its primary endpoint12%
- Stopped: enrollment or feasibility12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA